Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Doylestown, Pennsylvania
- Most recent report
- 10-Q, filed Aug 12, 2026
- Incorporated
- Delaware
- Filings on record
- 440 filings
- On EDGAR
- CIK 1781983
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer Smaller reporting company
Financials 8 of 30
News 8 of 92
- 8-K Quarterly results Aug 12, 2026
- 8-K Current report on a material event Jul 23, 2026
- 8-K Shareholder vote results Jun 17, 2026
- 8-K Quarterly results May 13, 2026
- 8-K Current report on a material event Apr 1, 2026
- 8-K Significant contract Mar 30, 2026
- 8-K Quarterly results Mar 16, 2026
- 8-K Other events Feb 18, 2026
Prospectuses and Registrations 8 of 34
- 424B3 Prospectus supplement for an offering Apr 29, 2026
- S-3 Shelf registration statement Apr 22, 2026
- 424B3 Prospectus supplement for an offering Mar 19, 2026
- S-3/A Shelf registration statement, amended Mar 17, 2026
- S-8 Registration statement for an employee plan Mar 16, 2026
- S-3 Shelf registration statement Feb 20, 2026
- 424B3 Prospectus supplement for an offering Dec 30, 2025
- S-3 Shelf registration statement Dec 19, 2025
Proxies 8 of 16
- DEFA14A Extra proxy material Apr 30, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 30, 2026
- PRE 14A Preliminary proxy statement Apr 20, 2026
- DEFA14A Extra proxy material Apr 22, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 22, 2025
- DEFA14A Extra proxy material Apr 25, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 25, 2024
- DEF 14A Proxy statement for a shareholder vote Jul 11, 2023
Ownership 8 of 229
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 13, 2026
- 4 Insider reported a trade Jun 17, 2026
- 4 Insider reported a trade Jun 17, 2026
- 4 Insider reported a trade Jun 17, 2026
- 4 Insider reported a trade Jun 17, 2026
- 4 Insider reported a trade Jun 17, 2026
- 4 Insider reported a trade Jun 17, 2026
- 4 Insider reported a trade Jun 17, 2026
Other 8 of 39
- 424B7 May 15, 2026
- ARS Annual report sent to shareholders Apr 30, 2026
- EFFECT Notice that a registration became effective Apr 29, 2026
- CORRESP Reply to SEC staff Apr 27, 2026
- UPLOAD Comment letter from SEC staff Apr 27, 2026
- EFFECT Notice that a registration became effective Mar 19, 2026
- EFFECT Notice that a registration became effective Dec 29, 2025
- D Dec 29, 2025
Everything here comes from Aprea Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.